Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Injected Vaccine Could Help Eradicate Polio

Published: Friday, July 11, 2014
Last Updated: Friday, July 11, 2014
Bookmark and Share
Re-introducing a type of polio vaccine that fell out of favour in the 1960s could hasten eradication of the disease.

Published in The Lancet, the study by Imperial College London and the Christian Medical College in Vellore, India, suggests that the injected polio vaccine (IPV), which is rarely used today in countries affected by polio, could provide better and longer lasting protection against infection if used in combination with the more commonly used live oral polio vaccine (OPV). 

Vaccination protects an individual against contracting polio, but they can still be infected by the virus, which replicates in the gut and can be passed to others through contact with infected faeces. This has led to serious polio outbreaks in Asia, Africa and Europe over the last 10 years and is hampering efforts to eradicate the disease. 

Most vaccination campaigns use multiple doses of OPV that provide some gut immunity, although this wanes over time.

"Because IPV is injected into the arm, rather than taken orally, it's been assumed it doesn't provide much protection in the gut and so would be less effective at preventing faecal transmission than OPV," explains Dr Jacob John, Associate Professor at the Christian Medical College, who led the study. "However, we found that where the children already had a level of immunity due to OPV, the injected vaccine actually boosted their gut immunity. 

"In the 1960s there was extensive rivalry between the scientists who developed the two vaccines, with OPV eventually becoming the most popular. But it looks as if the strongest immunity can been achieved through a combination of the two."

The study involved 450 children from a densely populated urban area in Vellore, India, all of whom had received the oral polio vaccine as part of a standard vaccination programme. Half of the children were given a dose of the injected vaccine and half given nothing. One month later, the children were given a 'challenge' dose of the live oral vaccine to simulate reinfection. 

Their stools were tested after seven days to see if the virus was present, specifically the two remaining serotypes of the virus which are resisting eradication - serotype 1 and serotype 3. In the children who had received the IPV, the researchers found that 38 per cent fewer had serotype 1 in their stool and 70 percent fewer had serotype 3, compared to those who had not been given the injected vaccine.

"Our findings show that an additional dose of the injected vaccine is more effective at boosting immunity against infection than the oral vaccine alone," says Nick Grassly, Professor of Vaccine Epidemiology at Imperial College London, senior author of the study. "This implies that the IPV could be used to boost immunity in people travelling from or to polio-infected countries, such as Afghanistan, Pakistan and Nigeria. It could also replace some of the OPV doses in immunisation campaigns to boost gut immunity, particularly in areas of poor sanitation."

In another study published this week in Proceedings of the National Academy of Sciences, Imperial researchers from the same group looked at whether expanding the age range of vaccination campaigns to include older children and adults would help to prevent polio transmission. Using a mathematical model to examine disease transmission in two major polio outbreaks in Tajikistan and the Republic of Congo in 2010, they found that older ages contributed significantly to transmission in Congo but not Tajikistan, which might be related to standards of sanitation and hygiene. However, launching mass immunisation campaigns more quickly in response to outbreaks would have a much bigger impact than expanding the age range, the study reported.

Lead author Dr Isobel Blake from the Medical Research Council Centre for Outbreak Analysis and Modelling at Imperial College London said: "It can take over 70 days to send stool samples to the lab and get back a diagnosis of polio, which means by the time authorities discover an outbreak, many more people are already infected. These findings suggest that methods to detect outbreaks earlier would be hugely beneficial to eradication efforts."

The Lancet study was funded by the Bill & Melinda Gates Foundation. The PNAS study was supported by a grant from the Polio Research Committee of the World Health Organization, the Royal Society, and Centre funding from the Medical Research Council.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protein That Boosts Immunity to Viruses and Cancer Discovered
Researchers now developing a gene therapy designed to boost the infection-fighting cells.
Saturday, April 18, 2015
Protein That Boosts Immunity To Viruses And Cancer Discovered
Scientists have discovered a protein that plays a central role in promoting immunity to viruses and cancer, opening the door to new therapies.
Friday, April 17, 2015
Adults Only Really Catch Flu About Twice a Decade, Suggests Study
Researchers developed a mathematical model of how our immunity to flu changes over a lifetime as we encounter different strains of the virus.
Thursday, March 05, 2015
Scientists Uncover New Role for Neurotransmitter that Helps Fight Infection
Scientists have shed new light on the complexities of the immune system that could help develop vaccines to boost natural defences against disease.
Wednesday, February 25, 2015
Epigenetic Study Highlights Drug Targets for Allergies and Asthma
Scientists have discovered over 30 new genes that predispose people to allergies and asthma, some of which could be targets for new drugs.
Saturday, February 21, 2015
New Class of Antibodies Raises Hope of Dengue Fever Vaccine
Scientists have discovered a new class of human antibodies against the dengue fever virus, which could be exploited to develop a vaccine.
Tuesday, February 03, 2015
Monitoring Effectiveness Of Hay Fever Immunotherapy
A new test for measuring histamine release from certain white blood cells could help doctors monitor the effectiveness of immunotherapy for hay fever.
Monday, November 24, 2014
Study Finds Potential New Target to Treat Asthma Attacks Brought on by Colds
Results suggest that IL-25 could be a target for possible treatments to prevent asthma attacks.
Tuesday, October 07, 2014
New Clues to How Bacteria Evade Antibiotics
Scientists have made an important advance in understanding how a subset of bacterial cells escape being killed by many antibiotics.
Friday, January 10, 2014
Scientists Closer to Universal Flu Vaccine After Pandemic “Natural Experiment”
The findings are published in Nature Medicine.
Friday, October 04, 2013
Researchers Pioneer Treatment for Viral Infection Common in Children
Professor Peter Openshaw and team develops a new technique used in tackling a wide range of other diseases.
Thursday, June 13, 2013
Flu is Transmitted Before Symptoms Appear, Study Suggests
ICL researchers examine influenza transmission in ferrets.
Wednesday, September 05, 2012
New Dean Appointed to Joint Medical School of Imperial College London and NTU
Immunology and infectious diseases pioneer, Professor Dermot Kelleher, to lead Lee Kong Chian School of Medicine.
Monday, August 06, 2012
Old Antibiotic could be a New Weapon to Fight TB
A cheap and safe antibiotic that is widely available in the developing world might have a new use as a TB treatment, according to new research.
Friday, February 17, 2012
Professor Dermot Kelleher Named as Principal of the Faculty of Medicine at ICL
Professor Kelleher is one of Ireland's foremost medical leaders and a pioneer in the field of immune response and infectious disease.
Monday, January 16, 2012
Scientific News
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Iron Regulators Join War on Pathogens
Iron regulatory proteins (IRPs) play an important role in the body’s immune system.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!